- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
APOLLO BEACH, Fla., January 14, 2026 (GLOBE NEWSWIRE) —RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”) a company developing ultra-high-resolution retinal imaging technology, today announced that a recent large‑scale Australian retinal mapping study, which used artificial intelligence to analyze approximately 50,000 retinal scans, reported that specific patterns of retinal thinning are associated with neurodegenerative and metabolic […]
Zwerling expected to guide the Company to its commercial launch.  APOLLO BEACH, Fla., December 8, 2025 (GLOBE NEWSWIRE) —RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”) a company developing ultra-high-resolution retinal imaging technology, combined with advanced genetic testing, today announced the signing of an agreement to hire M. Cory Zwerling as its chief financial officer […]
APOLLO BEACH, Fla., October 16, 2025 (GLOBE NEWSWIRE) —RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”), RetinalGenix Technologies Inc. (OTCQB:RTGN) (“RetinalGenix” or the “Company”), a company developing ultra-high-resolution retinal imaging technology, today announced it has engaged Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, to help identify […]
APOLLO BEACH, Fla., October 1, 2025 (GLOBE NEWSWIRE) —RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”), a pioneering developmental-stage company focused on ophthalmic screening, monitoring, pharmacogenetic mapping, and repurposed drug development for early detection and treatment of eye and systemic diseases, and RGEN Inc., a leader in genetic research and innovation (“RGEN”), today announced a strategic […]
APOLLO BEACH, Fla., September 25, 2025 (GLOBE NEWSWIRE) —RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”), RetinalGenix Technologies Inc. (OTCQB:RTGN) (“RetinalGenix” or the “Company”), a pioneering developmental-stage ophthalmic monitoring and biopharmaceutical company focused on early detection and treatments for eye and systemic diseases, is proud to announce significant advancements in its patent portfolio, helping to […]
